The Co-pay Assistance Program can provide financial support of up to $125 per month for 14 months.*
*For eligible patients.
†Data from April 2016 to April 2017.
‡Average nationwide coverage of methotrexate auto-injectors. Individual coverage may vary.
All brand or product names are registered trademarks of their respective owners.
*For eligible patients.
Utilize CORE Connections—a program that supports Rasuvo® (methotrexate) injection patients with educational materials, financial assistance, insurance forms, and more.
For reimbursement services and patient eligibility determinations, call the Rasuvo Benefits Support Line at 1-855-336-3322, from 9:00 AM to 6:00 PM EST Monday-Friday (excluding holidays).
Show your patients a video demonstration.
See Auto-Injector: 3 Easy Steps Video
Compared to the syringe and vial method of MTX administration, Rasuvo makes it easier to deliver MTX subcutaneously. The prefilled auto-injector eliminates the need for preparing doses by hand.3-5
Download the patient injection instruction sheet for complete instructions.
References: 1. Data on file. Medexus Pharma, Inc. 2. Rheumatoid arthritis database. Yardley, PA: Managed Markets Insight & Technology, LLC (MMIT): August 2019. 3. Demary W, Schwenke H, Rockwitz K, et al. Subcutaneously administered methotrexate for rheumatoid arthritis, by prefilled syringes versus prefilled pens: patient preference and comparison of the self-injection experience. Patient Prefer Adherence. 2014;8:1061-1071. 4. Pachon JA, Kivitz AJ, Heuer KU, Pichlmeier U. Assessing usability, label comprehension, pen robustness and pharmacokinetics of a self-administered prefilled autoinjector pen of methotrexate in patients with rheumatoid arthritis. SAGE Open Med. 2014;2:1-12. 5. Rasuvo [prescribing information]. Chicago, IL: Medac Pharma, Inc.; 2018.
Rasuvo is indicated for the:
Rasuvo is not indicated for treatment of neoplastic diseases.
This product includes the following Boxed Warning:
Rasuvo should be used only by physicians whose knowledge and experience include the use of antimetabolite therapy. Because of the possibility of serious toxic reactions (which can be fatal), Rasuvo should be used only in patients with psoriasis or rheumatoid arthritis with severe, recalcitrant, disabling disease which is not adequately responsive to other forms of therapy. Deaths have been reported with the use of methotrexate in the treatment of malignancy, psoriasis, and rheumatoid arthritis. Patients should be closely monitored for bone marrow, liver, lung, skin, and kidney toxicities. Patients should be informed by their physician of the risks involved and be under a physician's care throughout therapy.
Rasuvo is contraindicated in the following:
Common adverse reactions are: nausea, abdominal pain, dyspepsia, stomatitis/mouth sores, rash, nasopharyngitis, diarrhea, liver function test abnormalities, vomiting, headache, bronchitis, thrombocytopenia, alopecia, leukopenia, pancytopenia, dizziness, photosensitivity, and “burning of skin lesions”. The most frequently reported adverse reactions include ulcerative stomatitis, leukopenia, nausea, and abdominal distress. Other frequently reported adverse reactions are malaise, undue fatigue, chills and fever, dizziness and decreased resistance to infection.
Rasuvo is for once weekly subcutaneous use only.
Administer Rasuvo in the abdomen or thigh.